Cramer's Mad Dash: Abbott Labs

Summary

CNBC's Jim Cramer discussed Abbott Labs after the company signaled it would miss next quarter's numbers. He called Abbott a high-quality company but was bothered that the weakness is in diagnostics and that the cause is unclear. Cramer noted the Exact Sciences deal is on track and said he is weighing whether the selloff is a buying opportunity given management quality.

• Abbott Labs was indicated lower at the open.
• Cramer called Abbott a high-quality company with strong diagnostics, nutrition, and medical devices.
• Abbott told investors it will not make next quarter's numbers.
• Cramer was concerned that diagnostics, Abbott's core strength, is the source of weakness and the reason is unclear.
• The Exact Sciences acquisition was described as on track.
• Cramer said he is trying to decide if the weakness creates a buying opportunity.
• He cited Robert Ford's management as a positive factor.